MedPath

Development of clinically high efficient platforms for individualised treatment of cervix cancer

Not yet recruiting
Conditions
Malignant neoplasm of cervix uteri, unspecified,
Registration Number
CTRI/2021/08/035810
Lead Sponsor
Science and Engineering Research Board SERB
Brief Summary

Cervical cancer is the second most common cancer in India. Every year, around 80,000-90,000 women bear the burden of cervical cancer. In recent years, the use of advanced external radiation and brachytherapy techniques have improved the condition of the patients and their overall survival rates. This study proposal is an initiative with International collaborators to develop a robust model of efficient treatment delivery. In order to achieve this goal, we are making a move to integrate the knowledge of advanced technology, existing radiation treatment information, quantitative imaging, and available datasets from completed and ongoing clinical studies so that women diagnosed with Cervical cancer can be provided with highly precise treatment in a time-efficient manner. It is a retrospective study that will use existing database to develop automation and prediction tools.

**Study Aims**

1.      To develop and validate automated platforms for target delineation and planning for cervix cancer in time-efficient manner through

a.       Machine learning-based detection of abnormal cancerous tissues in multimodality medical diagnostic images.

b.      To train machine base systems for automated planning of external radiation and brachytherapy for gynaecological cancers.

2.      To use existing databases and radiation dose maps, imaging texture features and adverse events data for machine learning to develop “normal tissue complication plots “and to identify cervix cancer patient subgroups that may benefit from advanced radiation techniques (like proton treatment)

3.      To use advanced image texture analysis within ongoing institutional and collaborative clinical trials to identify “high-risk patient population†that may benefit from intensification of treatment in the future.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
1800
Inclusion Criteria
  • Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy.
  • Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.
Exclusion Criteria
  • Lack of disease or toxicity outcomes.
  • Lack of images in the hospital database.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
a) Generation of software for automated target delineation for cervix cancer.3 Years
b) Development and validation of Normal Tissue Complication Plots.3 Years
c) Identify “high risk patient population†that may benefit from intensification of treatment in future.3 Years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Advanced Centre for Treatment, Researc and Tata Memorial Hospital, Tata Memorial Centre

🇮🇳

Raigarh, MAHARASHTRA, India

Advanced Centre for Treatment, Researc and Tata Memorial Hospital, Tata Memorial Centre
🇮🇳Raigarh, MAHARASHTRA, India
Dr Supriya Chopra Sastri
Principal investigator
9930958309
supriyasastri@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.